Wechselwirkungen · Myclausen
Myclausen 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-212918 · Präparat HOS-155006
7 Ganciclovir Based on the results of a single dose administration study of recommended doses of oral mycophenolate and IV ganciclovir and the known effects of renal impairment on the pharmacokinetics of mycophenolate mofetil (see section 4.2) and ganciclovir, it is anticipated that co-administration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and ganciclovir concentration. No substantial alteration of MPA pharmacokinetics is anticipated and Myclausen dose adjustment is not required. In patients with renal impairment in whom Myclausen and ganciclovir or its prodrugs, e.g. valganciclovir, are co-administered, the dose recommendations for ganciclovir should be observed and patients should be monitored carefully.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): valganciclovir (HOS-085195) mycophenolate (HOS-085189) ganciclovir (HOS-085194)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T14:45:00Z · SHA-256 5212e91cac7f54413fc4524ec82e254c35610b87ec825a71d5d295c67a8c8df9 · Passage d27c48b80d087adde407820585d1f6713587c11b200cf932f61156e6bff0cf37 · Zeichen 5358–6141 im Abschnitt